STOCK TITAN

Inspira Technologies Releases CEO Update: Major Milestones Signal Next-Level Respiratory Care

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

Inspira Technologies (NASDAQ: IINN) CEO Dagi Ben Noon shared a comprehensive update on the company's progress in revolutionizing respiratory care. The company's flagship product, the INSPIRA ART500, aims to provide an alternative to mechanical ventilation for Acute Respiratory Failure patients.

Key developments include:

  • The INSPIRA ART100 system received FDA clearance in 2024 for Cardiopulmonary Bypass blood circulation
  • The HYLA Blood Sensor is targeting FDA submission in H2-2025
  • A Single-Use Patient Kit is planned for 2025/2026 FDA submissions
  • The INSPIRA ART500 FDA submission is projected within the next 18 months

The company is targeting the $19 billion global mechanical ventilation market and expects to receive a prepayment from its U.S. distributor for INSPIRA ART100 systems. The company is focusing its resources on accelerating the development of the INSPIRA ART500 system while exploring strategic distribution partnerships in Latam and Asia.

Inspira Technologies (NASDAQ: IINN) CEO Dagi Ben Noon ha condiviso un aggiornamento completo sui progressi dell'azienda nella rivoluzione della cura respiratoria. Il prodotto di punta dell'azienda, il INSPIRA ART500, mira a fornire un'alternativa alla ventilazione meccanica per i pazienti con insufficienza respiratoria acuta.

Le principali novità includono:

  • Il sistema INSPIRA ART100 ha ricevuto l'approvazione della FDA nel 2024 per la circolazione del sangue durante il bypass cardiopolmonare
  • Il HYLA Blood Sensor mira a presentare la domanda alla FDA nella seconda metà del 2025
  • Un kit per pazienti monouso è previsto per le domande alla FDA nel 2025/2026
  • La domanda per l'INSPIRA ART500 alla FDA è prevista entro i prossimi 18 mesi

L'azienda punta al mercato globale della ventilazione meccanica da 19 miliardi di dollari e si aspetta di ricevere un pagamento anticipato dal suo distributore statunitense per i sistemi INSPIRA ART100. L'azienda sta concentrando le proprie risorse per accelerare lo sviluppo del sistema INSPIRA ART500, esplorando nel contempo partnership strategiche di distribuzione in America Latina e Asia.

Inspira Technologies (NASDAQ: IINN) el CEO Dagi Ben Noon compartió una actualización integral sobre el progreso de la empresa en la revolución del cuidado respiratorio. El producto insignia de la empresa, el INSPIRA ART500, tiene como objetivo proporcionar una alternativa a la ventilación mecánica para pacientes con insuficiencia respiratoria aguda.

Los desarrollos clave incluyen:

  • El sistema INSPIRA ART100 recibió la aprobación de la FDA en 2024 para la circulación sanguínea durante el bypass cardiopulmonar
  • El HYLA Blood Sensor tiene como objetivo presentar la solicitud a la FDA en la segunda mitad de 2025
  • Un kit para pacientes de un solo uso está planeado para presentaciones a la FDA en 2025/2026
  • Se prevé que la presentación del INSPIRA ART500 a la FDA se realice en los próximos 18 meses

La empresa está apuntando al mercado global de ventilación mecánica de 19 mil millones de dólares y espera recibir un pago anticipado de su distribuidor en EE. UU. por los sistemas INSPIRA ART100. La empresa está enfocando sus recursos en acelerar el desarrollo del sistema INSPIRA ART500 mientras explora asociaciones estratégicas de distribución en América Latina y Asia.

Inspira Technologies (NASDAQ: IINN) CEO Dagi Ben Noon은 호흡 치료 혁신에 대한 회사의 진행 상황에 대한 포괄적인 업데이트를 공유했습니다. 회사의 주력 제품인 INSPIRA ART500은 급성 호흡 부전 환자를 위한 기계적 환기의 대안을 제공하는 것을 목표로 합니다.

주요 발전 사항은 다음과 같습니다:

  • INSPIRA ART100 시스템은 2024년에 심폐 우회 혈액 순환을 위해 FDA 승인을 받았습니다.
  • HYLA Blood Sensor는 2025년 하반기에 FDA 제출을 목표로 하고 있습니다.
  • 2025/2026년 FDA 제출을 위한 일회용 환자 키트가 계획되어 있습니다.
  • INSPIRA ART500의 FDA 제출은 향후 18개월 이내에 예정되어 있습니다.

회사는 190억 달러 규모의 글로벌 기계적 환기 시장을 목표로 하고 있으며, INSPIRA ART100 시스템에 대해 미국 유통업체로부터 선불금을 받을 것으로 기대하고 있습니다. 회사는 INSPIRA ART500 시스템의 개발을 가속화하는 데 자원을 집중하고 있으며, 라틴 아메리카와 아시아에서 전략적 유통 파트너십을 탐색하고 있습니다.

Inspira Technologies (NASDAQ: IINN) le PDG Dagi Ben Noon a partagé une mise à jour complète sur les progrès de l'entreprise dans la révolution des soins respiratoires. Le produit phare de l'entreprise, le INSPIRA ART500, vise à fournir une alternative à la ventilation mécanique pour les patients souffrant d'insuffisance respiratoire aiguë.

Les développements clés comprennent :

  • Le système INSPIRA ART100 a reçu l'approbation de la FDA en 2024 pour la circulation sanguine lors du pontage cardiopulmonaire
  • Le HYLA Blood Sensor vise à soumettre une demande à la FDA au second semestre 2025
  • Un kit patient à usage unique est prévu pour des soumissions à la FDA en 2025/2026
  • La soumission de l'INSPIRA ART500 à la FDA est prévue dans les 18 mois

L'entreprise cible le marché mondial de la ventilation mécanique de 19 milliards de dollars et s'attend à recevoir un paiement anticipé de son distributeur américain pour les systèmes INSPIRA ART100. L'entreprise concentre ses ressources sur l'accélération du développement du système INSPIRA ART500 tout en explorant des partenariats de distribution stratégiques en Amérique Latine et en Asie.

Inspira Technologies (NASDAQ: IINN) CEO Dagi Ben Noon teilte ein umfassendes Update über den Fortschritt des Unternehmens bei der Revolutionierung der Atemwegspflege. Das Flaggschiffprodukt des Unternehmens, das INSPIRA ART500, zielt darauf ab, eine Alternative zur mechanischen Beatmung für Patienten mit akuter Ateminsuffizienz zu bieten.

Wichtige Entwicklungen umfassen:

  • Das INSPIRA ART100 System erhielt 2024 die FDA-Zulassung für die Blutzirkulation bei der Herz-Lungen-Maschine
  • Der HYLA Blood Sensor zielt darauf ab, in der zweiten Hälfte von 2025 eine FDA-Einreichung vorzunehmen
  • Ein Einmalgebrauch-Patientenkit ist für FDA-Einreichungen in 2025/2026 geplant
  • Die FDA-Einreichung für das INSPIRA ART500 wird innerhalb der nächsten 18 Monate erwartet

Das Unternehmen zielt auf den 19 Milliarden US-Dollar umfassenden globalen Markt für mechanische Beatmung und erwartet eine Vorauszahlung von seinem US-Distributor für INSPIRA ART100 Systeme. Das Unternehmen konzentriert seine Ressourcen darauf, die Entwicklung des INSPIRA ART500 Systems zu beschleunigen, während es strategische Vertriebspartnerschaften in Lateinamerika und Asien erkundet.

Positive
  • FDA clearance already obtained for INSPIRA ART100 in 2024
  • Multiple product submissions planned for FDA approval in next 18 months
  • Targeting large $19B global mechanical ventilation market
  • Imminent prepayment expected from U.S. distributor
  • Strategic expansion planned in Latam and Asia markets
Negative
  • No current revenue or sales figures disclosed
  • Heavy focus on single product (ART500) could pose concentration risk
  • Multiple pending FDA approvals create regulatory uncertainty
  • Significant resources required for planned market expansion

Insights

Inspira Technologies' CEO letter reveals several key developments that signal momentum in its respiratory care product pipeline. The most concrete milestone is the FDA clearance of the INSPIRA ART100 platform in 2024, which has begun deployment in select U.S. centers for clinical evaluation. This establishes regulatory validation for the company's underlying technology platform.

Financially relevant is the disclosure that Inspira expects to receive a prepayment from its U.S. distributor for INSPIRA ART100 systems in the coming weeks. While no specific revenue figures are provided, this indicates the beginning of commercialization and potential near-term cash flow.

The company's ambitious target of the $19 billion global mechanical ventilation market shows substantial revenue potential if successful. Their strategy involves replacing a portion of the estimated 100,000 ventilators in the U.S. market with their less invasive alternative.

Most of Inspira's product pipeline remains in development with ambitious but uncertain timelines: their flagship INSPIRA ART500 system has a planned FDA submission within 18 months, their HYLA Blood Sensor is targeted for FDA submission in H2-2025, and their Single-Use Patient Kit is planned for 2025/2026 submissions.

The company is focusing its financial resources primarily on accelerating development of the INSPIRA ART500, which suggests careful cash management but also concentration risk on the success of this primary product.

Inspira Technologies is developing a potentially disruptive platform in critical respiratory care, with the primary innovation being their non-invasive approach compared to traditional mechanical ventilation. The INSPIRA ART500 system aims to elevate oxygen levels in patients with Acute Respiratory Failure without invasive mechanical ventilation—a significant clinical advantage if proven effective.

What separates this technology from conventional approaches is the patient-centered design allowing patients to remain awake and engaged during treatment, potentially reducing complications associated with sedation and intubation. The integrated HYLA Blood Sensor would eliminate routine blood draws, providing continuous monitoring—a meaningful workflow improvement for clinical staff and comfort enhancement for patients.

From a technological standpoint, Inspira has built a foundation with the FDA-cleared ART100 system for cardiopulmonary bypass applications, validating core elements of their technology platform. This regulatory clearance represents a significant de-risking event for their broader technology ecosystem.

The system's modular approach with disposable Single-Use Patient Kits suggests a recurring revenue model typical of successful medical device companies. However, the timeline for ART500 FDA submission within 18 months and other components in 2025/2026 indicates that full commercial realization remains years away.

Clinical adoption will ultimately depend on published efficacy data and cost-effectiveness compared to existing ventilation methods—neither of which are addressed in detail in this update.

Letter from the CEO / March 14, 2025

RA'ANANA, Israel, March 14, 2025 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. ("Inspira," "Inspira Technologies" or the "Company") (Nasdaq: IINN), a pioneering force in the evolution of respiratory support and real-time blood-monitoring technologies, is pleased to share this update to shareholders from its Chief Executive Officer, Director, and Co-founder, Mr. Dagi Ben Noon.

Dear Valued Shareholders,

We founded Inspira Technologies with a bold vision: to radically transform life-support for the millions of patients who each year face the harsh realities of mechanical ventilation. Today, I believe that the INSPIRA ART500 system we are developing stands poised to become the breakthrough solution that could profoundly reshape respiratory care.

In this letter, I want to provide my perspective on some of our recent achievements, how they connect to our strategic direction and long term vision, and some details on our upcoming roadmap.

1. INSPIRA ART500: A Transformational Leap in Critical Care

At the heart of our mission lies the INSPIRA ART500, a next-generation device designed to elevate oxygen levels for patients suffering from Acute Respiratory Failure - without resorting to invasive mechanical ventilation. Our aspiration is straightforward yet revolutionary: replace a significant portion of the estimated 100,000 ventilators in the U.S. with a safer, more human-centered alternative. Each INSPIRA ART500 device is expected to treat dozens of patients annually.

Over the past year, we've observed how similarly disruptive med-tech companies have generated remarkable investor enthusiasm, often driven by a confluence of regulatory achievements, compelling market demand, and strategic milestones. We believe the INSPIRA ART500 embodies that same, if not greater, potential for success. With cost control in mind, we are focusing most of the Company's financial resources on the acceleration of the disruptive INSPIRA ART500, in light of the product's potential superiority in the competitive landscape and value creation for the Company and its shareholders.

2. Multi-Pronged Technological Momentum & Accelerated Path to Market

INSPIRA ART500 is being designed to integrate multiple cutting-edge core technologies in the Company pipeline - all converging to redefine what's possible in critical care.

  • INSPIRA ART100 (FDA-Cleared in 2024)
    Our proprietary hardware and software platform, already cleared by the U.S. Food and Drug Administration ("FDA) for Cardiopulmonary Bypass blood circulation and oxygenation, has begun deployment in select U.S. centers for clinical use and evaluation by medical physicians. These initial sites will target capturing real-world performance data to fuel value creation towards further deployments and business development.
  • HYLA Blood Sensor (Targeted FDA Submission H2-2025)
    A unique, continuous, real-time blood-monitoring solution with the power to replace routine blood draws. Early clinical studies show strong accuracy and reliability - two factors that we expect will resonate with hospital networks worldwide.
  • Single-Use Patient Kit (Planned for 2025/2026 FDA Submissions)
    Incorporating advanced technologies for use with the INSPIRA ART500, the innovative kit includes components that are in direct contact with a patient's blood. These disposable elements are being designed to enhance patient safety and streamline workflow during procedures.

Taken together, these innovations are on track for pivotal studies shortly after the planned INSPIRA ART500 FDA submission - projected within the next 18 months. We believe the synergy among these technologies could ignite a wave of adoption in intensive care units across the globe.

3. Sizable Market Opportunity & Upcoming 18-Month Revenue Forecast

The global mechanical ventilation market is estimated at $19 billion annually. In the United States alone, tens of thousands of ventilators remain the backbone of critical care for severe respiratory conditions. INSPIRA ART500 aims to become the disruptive force that addresses this massive need with a safe, patient-friendly and less invasive approach.

In the coming weeks, the Company expects to receive a prepayment from its U.S. distributor for INSPIRA ART100 systems for planned deployment in select hospitals, a milestone that management believes underscores near-term revenue potential. 

4. Roadmap of Strategic Milestones

To build on this transformative momentum, we are aligning a series of key milestones to support sustained growth:

  1. Core Technologies: Focus of Company resources on the acceleration of development, regulatory and clinical efforts pertaining to the INSPIRA ART 500 system.
  2. Scaling U.S. Deployment: Collaborating with top-tier clinicians and institutions to expand post-market surveillance for the INSPIRA ART100 platform, reinforcing our clinical credibility.
  3. Strategic Alliances: Maintaining a resilient financial framework remains a priority. We're in discussions with prominent and global healthcare enterprises to fully capitalize on the potential of our INSPIRA ART100 product. 
  4. Global Distribution Agreements: Exploring strategic distribution partnerships in Latam and Asia, leveraging strong international demand for non-invasive respiratory solutions.

5. Envisioning the Future of Critical Care

Once fully integrated, our INSPIRA ART500 is intended to be equipped with the HYLA blood sensor. The single use patient kit aims to create a new and superior standard of patient-focused care. By allowing patients to stay awake and actively involved in their own recovery, we're not merely refining mechanical ventilation - we're redefining it.

6. A Personal Invitation to Our Investors

On behalf of the entire Inspira Technologies team, I want to thank you for your unwavering support and confidence in our vision. We're determined to lead a global shift in respiratory care - one that prioritizes patient dignity and significantly reduces the complications linked to conventional ventilation.

We invite you to stand with us as we reshape the landscape of acute respiratory care for millions of patients worldwide. Together, we have the opportunity to drive a wave of positive change in an industry that's ripe for disruption.

Warm Regards,

Dagi Ben Noon
CEO, Director, and Co-founder
Inspira Technologies

About Inspira Technologies

Inspira Technologies is developing innovative respiratory support and diagnostics technologies. The Company's flagship INSPIRA ART500 system also known as the INSPIRA ART aims to revolutionize critical care by enabling patients to remain awake during treatment while stabilizing oxygen levels without mechanical ventilation. The FDA-cleared INSPIRA ART100 system has received regulatory approvals for Cardiopulmonary Bypass procedures in both the U.S. and for Cardiopulmonary Bypass procedures and Extra Corporeal Membrane Oxygenation in Israel. The Company's HYLA™ blood sensor technology is designed to provide continuous, real-time blood monitoring without the need for blood draws. The Company's pipeline products, including the INSPIRA ART500, INSPIRA Cardi-ART, and HYLA blood sensor, are currently in development and have not yet received regulatory approval.

For more information, visit: https://inspira-technologies.com

Forward-Looking Statement Disclaimer

This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the potential benefits of the Company's products and impact on repository care and the market, that the INSPIRA ART500 device is expected to treat dozens of patients annually, its belief that the INSPIRA ART500 embodies the same or greater potential as other med-tech companies, the belief that the Company's innovations are on track for pivotal studies shortly after the planned INSPIRA ART FDA submission and that synergy among these technologies could ignite a wave of adoption in intensive care units worldwide, the expected timing of the FDA submission of the ART500, the HYLA blood sensor and single-use patient kit, the estimated size of the global mechanical ventilation market, the Company's aim to disrupt the existing approach with its technology, that the Company expects to receive  prepayment from its U.S. distributor for its devices for planned deployment in hospitals, the planned integration of the Company's devices, and the Company's belief that it has the opportunity to disrupt the mechanical ventilation market. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website at www.sec.gov.

Company Contact

Inspira Technologies – Media Relations
Email: info@inspirao2.com
Phone: +972-9-9664485

Capital Markets & Investor Contact

Arx | Capital Markets Advisors
North American Equities Desk
inspira@arxadvisory.com

 

Logo: https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg

 

Cision View original content:https://www.prnewswire.com/news-releases/inspira-technologies-releases-ceo-update-major-milestones-signal-next-level-respiratory-care-302401866.html

SOURCE Inspira Technologies

FAQ

When is Inspira Technologies (IINN) planning to submit the INSPIRA ART500 for FDA approval?

Inspira Technologies plans to submit the INSPIRA ART500 for FDA approval within the next 18 months from March 2025.

What is the market size that Inspira Technologies (IINN) is targeting with its respiratory care solutions?

Inspira Technologies is targeting the global mechanical ventilation market, estimated at $19 billion annually.

What FDA clearances has Inspira Technologies (IINN) already received for its products?

The INSPIRA ART100 received FDA clearance in 2024 for Cardiopulmonary Bypass blood circulation and oxygenation.

When is Inspira Technologies (IINN) planning to submit its HYLA Blood Sensor for FDA approval?

Inspira Technologies is targeting FDA submission for the HYLA Blood Sensor in the second half of 2025.

What immediate revenue potential does Inspira Technologies (IINN) expect?

The company expects to receive a prepayment from its U.S. distributor for INSPIRA ART100 systems for planned deployment in select hospitals.
Inspira Technologies Oxy Bhn Ltd

NASDAQ:IINN

IINN Rankings

IINN Latest News

IINN Stock Data

17.71M
23.23M
7.32%
4.97%
9.42%
Medical Devices
Healthcare
Link
Israel
Ra'anana